Fellow’s quick read · Infectious Diseases
Catheter-Associated Urinary Tract Infection (CAUTI)
IDSA 2010 (Hooton et al.) · reviewed 2026-08-17
Personal study digest for a new ID fellow. Recommendations are from the IDSA 2010 guideline (Hooton TM et al., CID 2010;50:625–663, doi:10.1086/650482). The “What’s changed since 2010” section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guideline.
In one line
CA-UTI requires symptoms plus ≥103 CFU/mL — a lower threshold than standard UTI. The single most impactful intervention is removing the catheter (or never placing it). Do not screen for or treat catheter-associated asymptomatic bacteriuria except in pregnant women or before urologic procedures with expected mucosal bleeding.◆When to suspect / diagnose
- CA-UTI definition: compatible symptoms (fever ≥38°C, rigors, new-onset delirium, flank pain, costovertebral angle tenderness, hematuria, pelvic discomfort) plus urine culture ≥103 CFU/mL of ≤2 species, in a patient with an indwelling catheter or within 48 h of catheter removal. Rec 1, A-III
- Pyuria is not diagnostic. Pyuria accompanies virtually all catheterized patients with bacteriuria (symptomatic or not). Its absence suggests a diagnosis other than CA-UTI. Rec 4, A-II / A-III
- Cloudy or foul-smelling urine is not an indication for urine culture or antimicrobial treatment. Rec 5, A-III
- Obtain urine culture before starting antibiotics (from a freshly placed catheter if the existing one has been in ≥2 weeks). Rec 45, A-III
◆Catheter management — the highest-yield intervention
- Remove the catheter ASAP. Prompt removal shortens bacteriuria duration and is the single most effective CAUTI prevention measure. Rec 10, A-I (bacteriuria) / A-II (CA-UTI)
- Nurse-initiated / electronic reminders to prompt catheter removal or reassessment reduce unnecessary catheter-days. Rec 11, A-II
- Automatic stop-orders (catheter removed unless clinician actively re-orders) reduce CAUTI. Rec 12, B-I
- Replace the catheter if in place ≥2 weeks at the time of CA-UTI diagnosis, before collecting the treatment culture (to improve microbiologic clearance). Rec 46, A-I
- Alternatives to indwelling catheters:
- Condom catheter in cooperative men — lower bacteriuria and CA-UTI vs indwelling. Rec 16, A-II (short-term) / B-II (long-term)
- Intermittent catheterization preferred over indwelling for patients with bladder-emptying dysfunction. Rec 17, A-III (long-term)
Do NOT screen or treat catheter-associated ASB
- Short-term catheterized: do not screen for or treat CA-ASB. Rec 41, A-II
- Long-term catheterized: do not screen for or treat CA-ASB. Rec 42, A-I
- Exceptions: screen and treat CA-ASB in pregnant women and patients undergoing urologic procedures with expected mucosal bleeding. Rec 43, A-III
◆Empiric & definitive therapy
The 2010 guideline does not prescribe specific empiric regimens — it directs empiric selection based on local antibiogram, gram stain, and prior cultures, then narrowing once susceptibilities return. The key treatment decisions:
| Decision | Recommendation | Strength |
|---|---|---|
| Culture before treating | Obtain urine culture from a freshly placed catheter before starting antibiotics | A-III |
| Replace catheter at treatment start | If catheter in place ≥2 wk, replace before collecting the specimen and starting Rx — improves symptom resolution and microbiologic clearance | A-I |
| Empiric choice | Base on local antibiogram, Gram stain, and any prior cultures; narrow once susceptibilities available | A-III |
| Candiduria | Symptomatic CA-UTI with Candida: fluconazole 200 mg/d × 14 d (fluconazole-susceptible); amphotericin B deoxycholate 0.3–0.6 mg/kg/d × 1–7 d for fluconazole-resistant species | A-III |
◆Duration & stopping
| Scenario | Duration | Strength |
|---|---|---|
| Prompt clinical response | 7 days | A-III |
| Delayed clinical response | 10–14 days | A-III |
| Non-severe CA-UTI, levofloxacin | 5 days (if levofloxacin chosen) | B-III |
| Women ≤65, catheter removed, no upper-tract symptoms | 3 days (treat as uncomplicated UTI) | B-II |
◆Prevention — what the fellow should reinforce
- No antimicrobial prophylaxis for catheterized patients — neither systemic nor intravesical. Rec 29, A-III (short-term) / A-II (long-term)
- No antimicrobial-coated or silver-alloy catheters to reduce CA-ASB or CA-UTI. Rec 25, A-I (silver) / A-II (antibiotic)
- No routine catheter changes at fixed intervals. Rec 31, A-III
- No cranberry products for CAUTI prevention. Rec 33, B-II
- No bladder irrigation with antimicrobials. Rec 30, A-I
- Aseptic insertion + closed drainage system remain standard. Rec 13, A-III / Rec 14, A-I
What’s changed since 2010
Reviewer synthesis — not the guideline. Each claim cited.
- No newer IDSA CAUTI management guideline — the 2010 document remains the current IDSA standard for CAUTI diagnosis and treatment. The field’s focus since 2010 has been on prevention, not updated treatment guidance.
- IDSA 2025 cUTI guidelines support shorter treatment — two companion papers (Trautner et al., CID 2025) provide the first IDSA guideline-level evidence on cUTI treatment since 2010. Key changes: 7 days is sufficient for improving cUTI (including with GN bacteremia); fluoroquinolones and TMP-SMX may allow 5–7 days; and step-wise empiric selection favors narrow-spectrum agents first. These shorten the 2010 guideline’s 10–14 day recommendation for delayed-response cases and provide stronger evidence for 7-day courses. doi:10.1093/cid/ciaf460; doi:10.1093/cid/ciaf462, PMID 41419448
- FDA 2016 fluoroquinolone boxed warning — strengthened warnings for tendinitis/rupture, peripheral neuropathy, and CNS effects. The 2010 guideline’s Rec 47 suggesting a 5-day levofloxacin course for non-severe CA-UTI remains pharmacologically valid but the risk-benefit calculus has shifted — FQs should be reserved for when narrower alternatives are not available. The 2025 cUTI guideline advises against FQs if the patient had FQ exposure in the prior 12 months. FDA Drug Safety Communication, 2016
- New antibiotics for resistant gram-negative cUTI (post-2010 FDA approvals) — six novel β-lactam/β-lactamase inhibitor combinations and siderophore cephalosporins are now available for ESBL and carbapenem-resistant organisms the 2010 guideline could not address: ceftolozane-tazobactam (2014), ceftazidime-avibactam (2015), meropenem-vaborbactam (2017), imipenem-cilastatin-relebactam (2019), cefiderocol (2019), and cefepime-enmetazobactam (2024). The 2025 IDSA cUTI guideline incorporates these into its step-wise empiric and definitive algorithms. doi:10.1093/cid/ciaf460
- SHEA/IDSA 2023 CAUTI Prevention Compendium — updated evidence synthesis for multimodal prevention bundles: nurse-driven catheter removal protocols, daily necessity checklists, and comprehensive unit-based safety programs consistently reduce CAUTI rates. Strengthens the 2010 guideline’s Recs 10–12 with 13 more years of implementation science. Buetti et al., ICHE 2023; PMID 37620117
- REPLACE trial (planned) — a protocol-stage non-inferiority RCT testing whether not replacing the catheter at the time of CA-UTI treatment is non-inferior to the 2010 guideline’s Rec 46 (always replace if in place ≥2 wk). Results pending; current practice should continue per Rec 46 until data are available. REPLACE trial protocol
- Still current — the core diagnostic framework (≥103 CFU/mL + symptoms), the injunction against treating CA-ASB (now reinforced by the 2019 ASB guideline), and the hierarchy of catheter alternatives (condom catheter, intermittent catheterization) all remain standard of care.
◆Anki cards minted this run
- CA-UTI diagnostic threshold — ≥103 CFU/mL + symptoms (lower than the ≥105 threshold for standard UTI).
- CA-ASB: do not treat — the two exceptions (pregnant women; pre-urologic-procedure with mucosal bleeding).
- Replace catheter at CA-UTI onset — if in place ≥2 weeks, replace before collecting specimen and starting treatment (A-I).
- 2025 IDSA cUTI duration update — 7 days for improving cUTI (including with GN bacteremia); shorter than the 2010 guideline’s 10–14 d for delayed responders.
Sources
- [1] Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–663. doi:10.1086/650482. PMID 20175247.
- [2] Trautner BW, Cortés-Penfield NW, Gupta K, et al. IDSA 2025 guideline on management and treatment of complicated UTI: antibiotic selection. Clin Infect Dis. 2025. doi:10.1093/cid/ciaf460.
- [3] Trautner BW, Cortés-Penfield NW, Gupta K, et al. IDSA 2025 guideline on management and treatment of complicated UTI: duration of antibiotics. Clin Infect Dis. 2025. doi:10.1093/cid/ciaf462. PMID 41419448.
- [4] Buetti N, Marschall J, Drees M, et al. Strategies to prevent catheter-associated urinary tract infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023;44(8):1209–1231. PMID 37620117.
- [5] FDA Drug Safety Communication: FDA updates warnings for fluoroquinolone antibiotics on risks of mental health side effects and low blood sugar. July 2016, updated December 2018.
- [6] Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by IDSA. Clin Infect Dis. 2019;68(10):e83–e75. doi:10.1093/cid/ciy1121.